News Medical2 小时
A deep dive in CAR+ T-cell therapy
In this article, Cerba dives into CAR+ T-cell therapy, from patient treatment to solutions for minimal residual disease (MRD) ...
Over 15 CD39-Targeted Treatments in Clinical Trials, Market Opportunity Surges by 2025
CD39-Targeted Therapies Near Key Milestones, First Approval Projected by 2029Dublin, Jan. 28, 2025 (GLOBE NEWSWIRE) -- The "CD39 Targeted Therapies Clinical Trials, Therapeutic Approaches & Market ...